Pay-for-Delay with Follow-On Products

被引:0
作者
Jorge Lemus
Emil Temnyalov
机构
[1] University of Illinois Urbana-Champaign,Department of Economics
[2] University of Technology Sydney,Department of Economics
来源
Review of Industrial Organization | 2020年 / 56卷
关键词
Antitrust; Evergreening; Litigation; Pay-for-delay; Product hopping;
D O I
暂无
中图分类号
学科分类号
摘要
We study pay-for-delay settlements between a patent-holder and a challenger when the patent-holder can introduce follow-on products. We show that ignoring follow-on products biases the inferred competitive harm of pay-for-delay settlements (the “Actavis inference”). The reason is that patent invalidation triggers an earlier introduction of follow-on products, which changes pay-for-delay negotiation payoffs. When follow-on products are ignored, we show that an inference based on a reverse payment over-estimates patent strength. If parties cannot use payments (as in pure-delay settlements), follow-on products may push the parties to settle on an earlier entry date, and litigation may arise in equilibrium.
引用
收藏
页码:697 / 714
页数:17
相关论文
共 35 条
[1]  
Bebchuk LA(1984)Litigation and settlement under imperfect information The RAND Journal of Economics 15 404-415
[2]  
Bulow J(2004)The gaming of pharmaceutical patents Innovation Policy and the Economy 4 145-187
[3]  
Carrier MA(2010)A real-world analysis of pharmaceutical settlements: The missing dimension of product hopping Florida Law Review 62 1009-424
[4]  
Carrier MA(2011)Provigil: A case study of anticompetitive behavior Hastings Science & Technology Law Journal 3 441-158
[5]  
Che YK(1993)The role of precedents in repeated litigation Journal of Law, Economics, & Organization 9 399-901
[6]  
Yi JG(2009)An economic assessment of patent settlements in the pharmaceutical industry Annals of Health Law 19 367-119
[7]  
Dickey B(2015)The Actavis inference: Theory and practice Rutgers University Law Review 67 585-38
[8]  
Orszag J(2016)Drug wars: A new generation of generic pharmaceutical delay Harvard Journal on Legislation 53 499-98
[9]  
Tyson L(2016)A new dimension to EU pharma antitrust product hopping and unilateral pay for delay European Competition Journal 12 137-55
[10]  
Edlin A(2017)A framework for estimating damages in reverse payment cases Antitrust Law Journal 81 873-undefined